The Woman Who Saved Thousands of American Children By Refusing to Trust

Welcome back to Crowdwits!

Our last two featured stories focused on cold cases – A Mother’s Plea, A Father’s March: The Lindsay Buziak Murder and How Ancestry Tests Became the Crowdsourcing Criminology Project Millions Joined Without Knowing. We explored how crowdsourcing can keep cold cases alive when official resources shift elsewhere.

This week, we're shifting from trusting crowds to questioning experts.

What happens when we can't trust the experts? When institutions designed to protect us become compromised by the very interests they're supposed to regulate? If you missed our examination of institutional corruption in politics, read this story about how money breaks trust in democracy.

This Sunday is International Women's Day. So, this week, we're honouring a woman you could trust in a system built on broken trust – Dr. Frances Kelsey, a Canadian scientist at the FDA who saved thousands of American children simply by refusing to approve a drug that everyone else had already accepted.

She refused to accept what others did. When supervisors pressured her, she held firm. While others took the pharmaceutical company's word—and the word of scientists promoting their drug—she demanded more evidence.

Frances Kelsey was a hero. This article honours her memory. Think about her this Sunday – along with all the important women in your life.

Not a Crowdwits subscriber yet? Or did someone forward you this email? Never miss a future issue ➡️ Subscribe for Free

The “Wonder Drug” That Wasn’t

In the 1950s, German company Chemie Grünenthal developed what it marketed as a miracle sleeping pill – safe for everyone, including pregnant women. The mild sedative also relieved morning sickness, making it especially popular among the population most vulnerable to its effects.

Then the reports started coming in.

Infant deaths. Catastrophic birth defects. Babies born without arms or legs.

Grünenthal denied any connection between thalidomide and these outcomes. The company held this position for years, even as the evidence mounted.

By the time the drug was banned in most countries in 1962, thousands of children had been born with severe deformities. Legal battles stretched across decades.

Kelsey's refusal saved thousands of American children from this fate. But only American children. Regulators in Canada and more than 20 other countries approved the drug she wouldn't trust.

What Did They Know?

If Dr. Kelsey spotted critical safety gaps in thalidomide's data, what did Grünenthal's scientists know?

They knew enough to use an "omit then deny" strategy: Don't run the tests, then claim such testing wasn't standard practice. No evidence means no liability.

Here's how it worked. In 1960, Dr. Kelsey requested specific data on thalidomide's effects on pregnant women and developing fetuses. The company didn't provide it – not because the tests were expensive or time-consuming, but because the results would have destroyed their market.

Instead, Grünenthal argued that fetal testing was uncommon. They built their entire defense on a gap they had deliberately created.

Kelsey's training in pharmacology helped her spot what was missing – evidence that should have been obvious to anyone reviewing the application properly.

Decades later, the company's CEO claimed Grünenthal had conducted all possible tests based on the latest science.

Kelsey's refusal proves otherwise.

The Pressure Scientists Face

We expect scientists to follow the evidence wherever it leads. To minimize bias, challenge assumptions, and uphold rigorous standards regardless of where they work.

Dr. Kelsey did exactly this when she resisted pressure from her FDA supervisors. But her hero status suggests something troubling: doing your job properly shouldn’t be exceptional.

This is institutional corruption: when organizational pressures systematically compromise professional standards. And scientists who depend on employment or research funding face real costs for maintaining strict principles.

Sometimes the corruption is subtle – unconscious. Relaxing standards gets rationalized as normal, acceptable. Hidden biases take root. Subtle decisions, often perfectly legal, distort research.

But it’s not always unconscious. Sometimes scientists deliberately curate their research to support predetermined outcomes – choosing which data to collect, which results to emphasize, which questions to ask. The line between rationalization and deliberate deception blurs when funding, careers, and colleagues’ jobs depend on producing the “right” results.

I explored this dilemma in an article in the Journal of Law, Medicine & Ethics, examining how institutional pressures shape research both inside universities and within pharmaceutical companies. The pressures look different, but the compromises can be equally damaging.

Grünenthal’s thalidomide case demonstrates both kinds of corruption

When German pediatrician Dr. Widukund Lenz suggested a link between thalidomide and birth deformities—while the drug was still being sold—Grünenthal allegedly threatened him with legal action.

The company also allegedly blocked medical publications. They convinced a medical journal to delay an article by neurologist Dr. Horst Frenkel demonstrating thalidomide’s dangerous side effects.

The drug remained on the market.

What Kelsey Teaches Us About Trust

Dr. Frances Kelsey worked until she was 90. At 100, she moved back to Canada to live with her daughter in London, Ontario. She died there last summer.

Her story illuminates something fundamental about our trust crisis: Sometimes the most heroic act is refusing to trust when everyone else does.

Kelsey didn't need extraordinary courage or whistleblower status. She just did her job properly – asked the questions that should have been asked, demanded the evidence that should have been provided, withstood pressure that shouldn't have existed.

Or perhaps more accurately: she maintained ethical and scientific integrity in a culture that had abandoned it for profit. She did what everyone else should have done – but didn't.

The fact that this made her a hero tells us everything about how broken the system was.

And remains.

Institutional corruption doesn't usually look like villains in a boardroom. It looks like subtle compromises – decisions that seem reasonable at the time, pressures that feel impossible to resist, rationalizations that allow good people to do harmful things.

Kelsey refused those compromises. That's what made the difference.

Understanding this is how we prevent the next thalidomide. Without it, we're doomed to repeat the same failures with different drugs, different companies, different victims.

This Sunday, International Women's Day, think about Frances Kelsey – a Canadian who stopped a tragedy in the United States.

She saved thousands of lives by doing something that should be ordinary: her job.

Garry C. Gray is a criminology professor at the University of Victoria and founder of Crowdwits, exploring crowdsourcing, institutional trust, and truth-seeking. He is a former Harvard Law School and Harvard School of Public Health research fellow, TEDx speaker on trust in research and institutional corruption, and was featured in CBC’s the Fifth Estate documentary Finding Emma for his crowdsourcing research.